Viral Vectors & Plasmid DNA Manufacturing Market Size, Share, and Trends 2024 to 2034

Chapter 1. Introduction

1.1. Research Objective
1.2. Scope of the Study
1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis

Chapter 5. Market Dynamics Analysis and Trends

5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition

Chapter 6. Competitive Landscape

6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers

Chapter 7. Global Viral Vectors & Plasmid DNA Manufacturing Market, By Vector Type

7.1. Viral Vectors & Plasmid DNA Manufacturing Market, by Vector Type, 2023-2032
7.1.1. Adenovirus
7.1.1.1. Market Revenue and Forecast (2021-2032)
7.1.2. Plasmid DNA
7.1.2.1. Market Revenue and Forecast (2021-2032)
7.1.3. Lentivirus
7.1.3.1. Market Revenue and Forecast (2021-2032)
7.1.4. Retrovirus
7.1.4.1. Market Revenue and Forecast (2021-2032)
7.1.5. AAV
7.1.5.1. Market Revenue and Forecast (2021-2032)
7.1.6. Others
7.1.6.1. Market Revenue and Forecast (2021-2032)

Chapter 8. Global Viral Vectors & Plasmid DNA Manufacturing Market, By Application Type

8.1. Viral Vectors & Plasmid DNA Manufacturing Market, by Application Type, 2023-2032
8.1.1. Gene Therapy
8.1.1.1. Market Revenue and Forecast (2021-2032)
8.1.2. Antisense &RNAi
8.1.2.1. Market Revenue and Forecast (2021-2032)
8.1.3. Cell Therapy
8.1.3.1. Market Revenue and Forecast (2021-2032)
8.1.4. Vaccinology
8.1.4.1. Market Revenue and Forecast (2021-2032)

Chapter 9. Global Viral Vectors & Plasmid DNA Manufacturing Market, By Workflow Type

9.1. Viral Vectors & Plasmid DNA Manufacturing Market, by Workflow Type, 2023-2032
9.1.1. Upstream Processing (Vector Recovery/Harvesting, Vector Amplification & Expansion)
9.1.1.1. Market Revenue and Forecast (2021-2032)
9.1.2. Downstream Processing (Fill-finish, Purification)
9.1.2.1. Market Revenue and Forecast (2021-2032)

Chapter 10. Global Viral Vectors & Plasmid DNA Manufacturing Market, By End-User Type

10.1. Viral Vectors & Plasmid DNA Manufacturing Market, by End-User Type, 2023-2032
10.1.1. Biopharmaceutical and Pharmaceutical Companies
10.1.1.1. Market Revenue and Forecast (2021-2032)
10.1.2. Research Institutes
10.1.2.1. Market Revenue and Forecast (2021-2032)

Chapter 11. Global Viral Vectors & Plasmid DNA Manufacturing Market, By Disease

11.1. Viral Vectors & Plasmid DNA Manufacturing Market, by Disease, 2023-2032
11.1.1. Genetic Disorders
11.1.1.1. Market Revenue and Forecast (2021-2032)
11.1.2. Cancer
11.1.2.1. Market Revenue and Forecast (2021-2032)
11.1.3. Infectious Diseases
11.1.3.1. Market Revenue and Forecast (2021-2032)
11.1.4. Others
11.1.4.1. Market Revenue and Forecast (2021-2032)

Chapter 12. Global Viral Vectors & Plasmid DNA Manufacturing Market, Regional Estimates and Trend Forecast

12.1. North America
12.1.1. Market Revenue and Forecast, by Vector (2021-2032)
12.1.2. Market Revenue and Forecast, by Application (2021-2032)
12.1.3. Market Revenue and Forecast, by Workflow (2021-2032)
12.1.4. Market Revenue and Forecast, by End-User (2021-2032)
12.1.5. Market Revenue and Forecast, by Disease (2021-2032)
12.1.6. U.S.
12.1.6.1. Market Revenue and Forecast, by Vector (2021-2032)
12.1.6.2. Market Revenue and Forecast, by Application (2021-2032)
12.1.6.3. Market Revenue and Forecast, by Workflow (2021-2032)
12.1.6.4. Market Revenue and Forecast, by End-User (2021-2032)
12.1.7. Market Revenue and Forecast, by Disease (2021-2032)
12.1.8. Rest of North America
12.1.8.1. Market Revenue and Forecast, by Vector (2021-2032)
12.1.8.2. Market Revenue and Forecast, by Application (2021-2032)
12.1.8.3. Market Revenue and Forecast, by Workflow (2021-2032)
12.1.8.4. Market Revenue and Forecast, by End-User (2021-2032)
12.1.9. Market Revenue and Forecast, by Disease (2021-2032)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Vector (2021-2032)
12.2.2. Market Revenue and Forecast, by Application (2021-2032)
12.2.3. Market Revenue and Forecast, by Workflow (2021-2032)
12.2.4. Market Revenue and Forecast, by End-User (2021-2032)
12.2.5. Market Revenue and Forecast, by Disease (2021-2032)
12.2.6. UK
12.2.6.1. Market Revenue and Forecast, by Vector (2021-2032)
12.2.6.2. Market Revenue and Forecast, by Application (2021-2032)
12.2.6.3. Market Revenue and Forecast, by Workflow (2021-2032)
12.2.7. Market Revenue and Forecast, by End-User (2021-2032)
12.2.8. Market Revenue and Forecast, by Disease (2021-2032)
12.2.8.1. Market Revenue and Forecast, by Raw Material (2021-2032)
12.2.9. Germany
12.2.9.1. Market Revenue and Forecast, by Vector (2021-2032)
12.2.9.2. Market Revenue and Forecast, by Application (2021-2032)
12.2.9.3. Market Revenue and Forecast, by Workflow (2021-2032)
12.2.10. Market Revenue and Forecast, by End-User (2021-2032)
12.2.11. Market Revenue and Forecast, by Disease (2021-2032)
12.2.12. France
12.2.12.1. Market Revenue and Forecast, by Vector (2021-2032)
12.2.12.2. Market Revenue and Forecast, by Application (2021-2032)
12.2.12.3. Market Revenue and Forecast, by Workflow (2021-2032)
12.2.12.4. Market Revenue and Forecast, by End-User (2021-2032)
12.2.13. Market Revenue and Forecast, by Disease (2021-2032)
12.2.14. Rest of Europe
12.2.14.1. Market Revenue and Forecast, by Vector (2021-2032)
12.2.14.2. Market Revenue and Forecast, by Application (2021-2032)
12.2.14.3. Market Revenue and Forecast, by Workflow (2021-2032)
12.2.14.4. Market Revenue and Forecast, by End-User (2021-2032)
12.2.15. Market Revenue and Forecast, by Disease (2021-2032)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Vector (2021-2032)
12.3.2. Market Revenue and Forecast, by Application (2021-2032)
12.3.3. Market Revenue and Forecast, by Workflow (2021-2032)
12.3.4. Market Revenue and Forecast, by End-User (2021-2032)
12.3.5. Market Revenue and Forecast, by Disease (2021-2032)
12.3.6. India
12.3.6.1. Market Revenue and Forecast, by Vector (2021-2032)
12.3.6.2. Market Revenue and Forecast, by Application (2021-2032)
12.3.6.3. Market Revenue and Forecast, by Workflow (2021-2032)
12.3.6.4. Market Revenue and Forecast, by End-User (2021-2032)
12.3.7. Market Revenue and Forecast, by Disease (2021-2032)
12.3.8. China
12.3.8.1. Market Revenue and Forecast, by Vector (2021-2032)
12.3.8.2. Market Revenue and Forecast, by Application (2021-2032)
12.3.8.3. Market Revenue and Forecast, by Workflow (2021-2032)
12.3.8.4. Market Revenue and Forecast, by End-User (2021-2032)
12.3.9. Market Revenue and Forecast, by Disease (2021-2032)
12.3.10. Japan
12.3.10.1. Market Revenue and Forecast, by Vector (2021-2032)
12.3.10.2. Market Revenue and Forecast, by Application (2021-2032)
12.3.10.3. Market Revenue and Forecast, by Workflow (2021-2032)
12.3.10.4. Market Revenue and Forecast, by End-User (2021-2032)
12.3.10.5. Market Revenue and Forecast, by Disease (2021-2032)
12.3.11. Rest of APAC
12.3.11.1. Market Revenue and Forecast, by Vector (2021-2032)
12.3.11.2. Market Revenue and Forecast, by Application (2021-2032)
12.3.11.3. Market Revenue and Forecast, by Workflow (2021-2032)
12.3.11.4. Market Revenue and Forecast, by End-User (2021-2032)
12.3.11.5. Market Revenue and Forecast, by Disease (2021-2032)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Vector (2021-2032)
12.4.2. Market Revenue and Forecast, by Application (2021-2032)
12.4.3. Market Revenue and Forecast, by Workflow (2021-2032)
12.4.4. Market Revenue and Forecast, by End-User (2021-2032)
12.4.5. Market Revenue and Forecast, by Disease (2021-2032)
12.4.6. GCC
12.4.6.1. Market Revenue and Forecast, by Vector (2021-2032)
12.4.6.2. Market Revenue and Forecast, by Application (2021-2032)
12.4.6.3. Market Revenue and Forecast, by Workflow (2021-2032)
12.4.6.4. Market Revenue and Forecast, by End-User (2021-2032)
12.4.7. Market Revenue and Forecast, by Disease (2021-2032)
12.4.8. North Africa
12.4.8.1. Market Revenue and Forecast, by Vector (2021-2032)
12.4.8.2. Market Revenue and Forecast, by Application (2021-2032)
12.4.8.3. Market Revenue and Forecast, by Workflow (2021-2032)
12.4.8.4. Market Revenue and Forecast, by End-User (2021-2032)
12.4.9. Market Revenue and Forecast, by Disease (2021-2032)
12.4.10. South Africa
12.4.10.1. Market Revenue and Forecast, by Vector (2021-2032)
12.4.10.2. Market Revenue and Forecast, by Application (2021-2032)
12.4.10.3. Market Revenue and Forecast, by Workflow (2021-2032)
12.4.10.4. Market Revenue and Forecast, by End-User (2021-2032)
12.4.10.5. Market Revenue and Forecast, by Disease (2021-2032)
12.4.11. Rest of MEA
12.4.11.1. Market Revenue and Forecast, by Vector (2021-2032)
12.4.11.2. Market Revenue and Forecast, by Application (2021-2032)
12.4.11.3. Market Revenue and Forecast, by Workflow (2021-2032)
12.4.11.4. Market Revenue and Forecast, by End-User (2021-2032)
12.4.11.5. Market Revenue and Forecast, by Disease (2021-2032)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Vector (2021-2032)
12.5.2. Market Revenue and Forecast, by Application (2021-2032)
12.5.3. Market Revenue and Forecast, by Workflow (2021-2032)
12.5.4. Market Revenue and Forecast, by End-User (2021-2032)
12.5.5. Market Revenue and Forecast, by Disease (2021-2032)
12.5.6. Brazil
12.5.6.1. Market Revenue and Forecast, by Vector (2021-2032)
12.5.6.2. Market Revenue and Forecast, by Application (2021-2032)
12.5.6.3. Market Revenue and Forecast, by Workflow (2021-2032)
12.5.6.4. Market Revenue and Forecast, by End-User (2021-2032)
12.5.7. Market Revenue and Forecast, by Disease (2021-2032)
12.5.8. Rest of LATAM
12.5.8.1. Market Revenue and Forecast, by Vector (2021-2032)
12.5.8.2. Market Revenue and Forecast, by Application (2021-2032)
12.5.8.3. Market Revenue and Forecast, by Workflow (2021-2032)
12.5.8.4. Market Revenue and Forecast, by End-User (2021-2032)
12.5.8.5. Market Revenue and Forecast, by Disease (2021-2032)

Chapter 13. Company Profiles

13.1. Novasep
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Aldevron
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Merck Waisman Biomanufacturing
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Creative Biogene
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. The Cell and Gene Therapy Catapult
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Cobra Biologics
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. uniQure N.V.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Addgene
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. FUJIFILM Holdings Corporation
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Oxford Biomedicaplc
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
13.11. Takara Bio Inc.
13.11.1. Company Overview
13.11.2. Product Offerings
13.11.3. Financial Performance
13.11.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions

Chapter 15. Appendix

15.1. About Us
15.2. Glossary of Terms